文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.

作者信息

Arf Serra, Hocaoglu Mumin, Sayman Muslubas Isil, Karacorlu Murat

机构信息

Istanbul RETINA Institute, Hakkı Yeten Cad. Unimed Center No: 19/7 Fulya Şişli, Istanbul, 34349, Turkey.

出版信息

Int Ophthalmol. 2017 Jun;37(3):483-489. doi: 10.1007/s10792-016-0286-4. Epub 2016 Jul 8.


DOI:10.1007/s10792-016-0286-4
PMID:27392913
Abstract

The purpose of the study was to evaluate the effect of reduced-fluence photodynamic therapy (RFPDT) for chronic central serous chorioretinopathy (CSC) associated with serous retinal detachment (SRD) and fovea-involving pigment epithelial detachment (PED). Ten eyes of ten patients with chronic CSC associated with combined SRD and PED involving the fovea were included. RFPDT was applied to the hyperfluorescent area identified at the mid-to-late phase of indocyanine green angiography, which indicated the area of leakage. We evaluated the changes in best-corrected visual acuity (BCVA) and optical coherence tomography at month 1 and final follow-up visit. The mean age of the participants was 47.4 ± 7 years. The mean follow-up duration was 6.3 ± 4 months. At month 3, the SRD had resolved completely in all ten eyes (100 %), and PED had resolved in seven eyes (70 %). The initial mean BCVA improved from 20/50 at baseline to 20/32 at the last visit (P > 0.05). The mean central retinal thickness was reduced from 534 ± 279 µm at baseline to 194 ± 46 µm at the last examination (P < 0.001). The mean subfoveal choroidal thickness decreased from 461 ± 57 at baseline to 369 ± 75 at the final visit (P < 0.001). Reduced-fluence PDT appears as an effective treatment for chronic CSC cases associated with SRD and fovea-involving PED.

摘要

相似文献

[1]
Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment.

Int Ophthalmol. 2017-6

[2]
Reduced-fluence photodynamic therapy for subfoveal serous pigment epithelial detachment with choroidal vascular hyperpermeability.

Am J Ophthalmol. 2012-7-27

[3]
Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.

Semin Ophthalmol. 2018

[4]
PHOTODYNAMIC THERAPY FOR SYMPTOMATIC SUBFOVEAL RETINAL PIGMENT EPITHELIAL DETACHMENT IN CENTRAL SEROUS CHORIORETINOPATHY: Outcomes and Prognostic Factors.

Retina. 2019-6

[5]
Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.

Retina. 2011-10

[6]
[Photodynamic therapy for chronic central serous chorioretinopathy and diffuse retinal epitheliopathy].

J Fr Ophtalmol. 2012-2

[7]
Isolated pigment epithelium detachment: evidence for relation to central serous chorioretinopathy and effect of photodynamic therapy.

Acta Ophthalmol. 2018-9-23

[8]
Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.

Graefes Arch Clin Exp Ophthalmol. 2017-10

[9]
Comparison of half-dose photodynamic therapy and 689 nm laser treatment in eyes with chronic central serous chorioretinopathy.

Graefes Arch Clin Exp Ophthalmol. 2017-6

[10]
CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Early and Late Morphological and Functional Changes After Verteporfin Photodynamic Therapy.

Retina. 2019-5

引用本文的文献

[1]
A Review of Central Serous Chorioretinopathy: Clinical Presentation and Management.

Cureus. 2022-8-13

[2]
Regression patterns of central serous chorioretinopathy using en face optical coherence tomography.

Graefes Arch Clin Exp Ophthalmol. 2022-8

[3]
Improved thickness measurement method for choroidal hyperpermeability in central serous chorioretinopathy.

Int J Ophthalmol. 2020-9-18

[4]
Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy.

PLoS One. 2018-8-24

本文引用的文献

[1]
Photodynamic therapy for central serous chorioretinopathy.

Eye (Lond). 2014-8

[2]
Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.

Ophthalmology. 2014-1-16

[3]
Central serous chorioretinopathy: update on pathophysiology and treatment.

Surv Ophthalmol. 2013

[4]
Reduced-fluence photodynamic therapy for subfoveal serous pigment epithelial detachment with choroidal vascular hyperpermeability.

Am J Ophthalmol. 2012-7-27

[5]
Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy.

Retina. 2011-10

[6]
Microperimetric changes after photodynamic therapy for central serous chorioretinopathy.

Am J Ophthalmol. 2010-12-18

[7]
Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy.

Retina. 2011-1

[8]
Photodynamic therapy for chronic central serous chorioretinopathy.

Acta Ophthalmol. 2009-11-27

[9]
Prognostic factors related to photodynamic therapy for central serous chorioretinopathy.

Graefes Arch Clin Exp Ophthalmol. 2009-10

[10]
Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.

Ophthalmology. 2008-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索